Aytu BioPharma (NASDAQ:AYTU) Share Price Passes Below Fifty Day Moving Average – Here’s What Happened

Shares of Aytu BioPharma Inc. (NASDAQ:AYTU) crossed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $2.54 and traded as low as $2.03. Aytu BioPharma shares last traded at $2.15, with a volume of 29,458 shares changing hands.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Zacks Research raised Aytu BioPharma from a “strong sell” rating to a “hold” rating in a report on Monday, May 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aytu BioPharma in a report on Wednesday, April 8th. Finally, Wall Street Zen raised Aytu BioPharma to a “hold” rating in a report on Saturday, February 7th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $9.33.

Aytu BioPharma Trading Up 3.4%

The firm has a fifty day simple moving average of $2.54 and a two-hundred day simple moving average of $2.44. The firm has a market capitalization of $23.07 million, a P/E ratio of -0.47 and a beta of 0.28. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.12 and a quick ratio of 1.00.

Aytu BioPharma (NASDAQ:AYTU) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.09). Aytu BioPharma had a negative net margin of 60.17% and a negative return on equity of 69.93%. The firm had revenue of $12.41 million for the quarter, compared to the consensus estimate of $12.05 million. On average, equities research analysts anticipate that Aytu BioPharma Inc. will post -0.69 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aytu BioPharma

Institutional investors and hedge funds have recently bought and sold shares of the company. Persistent Asset Partners Ltd purchased a new stake in shares of Aytu BioPharma during the third quarter worth $117,000. Dimensional Fund Advisors LP purchased a new stake in shares of Aytu BioPharma during the third quarter worth $58,000. Two Sigma Investments LP lifted its position in shares of Aytu BioPharma by 96.2% during the third quarter. Two Sigma Investments LP now owns 68,736 shares of the company’s stock worth $129,000 after acquiring an additional 33,701 shares in the last quarter. FNY Investment Advisers LLC lifted its position in shares of Aytu BioPharma by 24,207.7% during the fourth quarter. FNY Investment Advisers LLC now owns 31,600 shares of the company’s stock worth $82,000 after acquiring an additional 31,470 shares in the last quarter. Finally, Daytona Street Capital LLC purchased a new stake in shares of Aytu BioPharma during the fourth quarter worth $26,000. 33.49% of the stock is owned by institutional investors.

About Aytu BioPharma

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.